期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

吉非替尼治疗非小细胞肺癌致间质性肺炎1例 被引量：1

下载PDF
导出
摘要 吉非替尼（Gefitinib，易瑞沙）是AstraZenica公司开发的分子靶向治疗药物，其目前获准的适应证为治疗既往接受过化疗或不适于化疗的局部晚期或转移性的NSCLC以及一线治疗存在EGFR基因特定位点突变的晚期NSCLC。间质性肺疾病是吉非替尼引起的少见、但可致命的严重不良反应。现报道1例晚期肺癌患者口服吉非替尼治疗致间质性肺炎的情况。
作者 王晖 管湘萍 苑东明
机构地区 潍坊医学院附属诸城人民医院呼吸内科
出处 《中国实用医药》 2013年第6期186-187,共2页 China Practical Medicine
关键词 靶向治疗药物 间质性肺炎 吉非替尼 非小细胞肺癌 晚期NSCLC EGFR基因 间质性肺疾病 严重不良反应
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献5

  • 1蒋敏,钱晓萍,刘宝瑞.吉非替尼治疗非小细胞肺癌研究进展[J].现代肿瘤医学,2009,17(10):2026-2029. 被引量：14
  • 2Von Pawel J. Gefitinib ( Iressa, ZD 1839 ) : a novel targeted ap-proach for the treatment of solid tumors. Bull Cancer,2004,91 (5):E70 -76.
  • 3Ando M, Okamo to I,Yamamoto N, et al. Predictiv e factors forinterstit ial lung disease, antitumor response,andsurv ival in no n-smal-1 cell lung cancer patients treated w ithg efitinib. J Clin OncoI,2006,24(16) : 2549- 2556.
  • 4Cerso simo RJ. Gefitinib: an adverse effects pr ofile. Expert OpinDrug Saf, 2006, 5(3) : 469-479.
  • 5Okamoto I, Fujii K, Matsumoto M,et al. Diffuse alveolar damageafterZD1839 therapy in a patient with non-small cell lung cancer.LungCancer,2003,40(3) : 339 - 442.

二级参考文献24

  • 1Cragg MS , Kuroda J , Puthalakath H, et al . Gefitnib - induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics [ J ]. Plos Med, 2007,4 (10) :1681 - 1689.
  • 2Costa DB,Halmos B, Kumar A , et al. BIM mediates EGFR tyrosinekinase inhibitor - induced apoptosis in lung cancers with oncogenic EGFR mutations [ J ]. Plos Med, 2007,4 ( 10 ) : 1669 - 1679.
  • 3Chang A, Parikh P, Thongprasert S, et al. Gefitinib ( IRESSA ) in patients of Asian origin with refractory advanced non - small cell lung cancer:subset analysis from the ISEL study[ J ]. Thora Oneol, 2006,1 (8) : 847 - 855.
  • 4Lynch TJ , Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non - small - cell lung cancer to gefitinib[ J ] . N Engl J Med ,200g ,350 (21) :2129 -2139.
  • 5Sordella R, Bell DW, Haber DA, et al. Gefitinib - sensitizing EGFR mutations in lung cancer activate anti - apoptotic pathways [ J ]. Science,2004,305 (5687) : 1163 - 1167.
  • 6Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non - small - cell lung cancer patients treated with gefitinib [ J ]. J Clin Oncol, 2005,23 ( 11 ) :2493 - 2501.
  • 7Cappuzzo F,Han SW,Kim TY,et al. Predictive and prognostic impact of epidermal growth factor receptor gene and protein and gefitinib sensitivity in non - small - cell lung cancer[ J]. J Natl Cancer Inst,2005,97(9) :643 -655.
  • 8Eberhard DA ,Johnson BE ,AmLer LC ,et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non - small - cell lung cancer treated with chemotherapy alone and in combination with erlotinib [ J ]. J Clin Oncol,2005,23 ( 25 ) :5900 - 5909.
  • 9Tomizawa Y, Iijima H, Sunaga N, et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non - small cell Lung cancer [ J ] . Clin Cancer Res,2005,11 (19) :6816 -6822.
  • 10Shigematsu H , Li L , Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers [ J ]. J Natl Cancer Inst,2005,97 ( 5 ) : 339 - 346.

共引文献13

同被引文献24

引证文献1

二级引证文献14

中国实用医药
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部